Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The contemporary management of cancers of the sinonasal tract in adults.
Thawani R, Kim MS, Arastu A, Feng Z, West MT, Taflin NF, Thein KZ, Li R, Geltzeiler M, Lee N, Fuller CD, Grandis JR, Floudas CS, Heinrich MC, Hanna E, Chandra RA. Thawani R, et al. Among authors: heinrich mc. CA Cancer J Clin. 2023 Jan;73(1):72-112. doi: 10.3322/caac.21752. Epub 2022 Aug 2. CA Cancer J Clin. 2023. PMID: 35916666 Free PMC article. Review.
Paraganglioma of the Head and Neck: A Review.
Sandow L, Thawani R, Kim MS, Heinrich MC. Sandow L, et al. Among authors: heinrich mc. Endocr Pract. 2023 Feb;29(2):141-147. doi: 10.1016/j.eprac.2022.10.002. Epub 2022 Oct 15. Endocr Pract. 2023. PMID: 36252779 Free PMC article. Review.
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?
Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Thirasastr P, et al. Among authors: heinrich mc. Cancers (Basel). 2024 Feb 23;16(5):904. doi: 10.3390/cancers16050904. Cancers (Basel). 2024. PMID: 38473266 Free PMC article.
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
Schöffski P, George S, Heinrich MC, Zalcberg JR, Bauer S, Gelderblom H, Serrano C, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Becker C, Shi K, Meade J, Ruiz-Soto R, Blay JY, von Mehren M. Schöffski P, et al. Among authors: heinrich mc. BMC Cancer. 2022 Dec 13;22(1):1302. doi: 10.1186/s12885-022-10379-9. BMC Cancer. 2022. PMID: 36514034 Free PMC article. Clinical Trial.
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Gelderblom H, et al. Among authors: heinrich mc. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. Eur J Cancer. 2023. PMID: 37598656 Free article. Clinical Trial.
Novel trial designs for patients with gastrointestinal stromal tumor.
Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Serrano C, et al. Among authors: heinrich mc. ESMO Open. 2024 Jan;9(1):102218. doi: 10.1016/j.esmoop.2023.102218. Epub 2024 Jan 8. ESMO Open. 2024. PMID: 38194880 Free PMC article. No abstract available.
279 results